# Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

> **NCT00407355** · PHASE1,PHASE2 · COMPLETED · sponsor: **Peter A Campochiaro, MD** · enrollment: 40 (actual)

## Conditions studied

- Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** Intravitreal injection of ranibizumab .3 dose
- **DRUG:** Intravitreal injection of Ranibizumab .5 dose

## Key facts

- **NCT ID:** NCT00407355
- **Lead sponsor:** Peter A Campochiaro, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407355, "Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00407355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*